{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:35:44Z","timestamp":1789500944445,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.pnpbp.2007.04.020","type":"journal-article","created":{"date-parts":[[2007,5,11]],"date-time":"2007-05-11T11:47:15Z","timestamp":1178884035000},"page":"1153-1163","source":"Crossref","is-referenced-by-count":27,"title":["Selegiline transdermal system: Current awareness and promise"],"prefix":"10.1016","volume":"31","author":[{"given":"Chi-Un","family":"Pae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Kook","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajwani","family":"Neena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin A.","family":"Patkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2007.04.020_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000008188","article-title":"Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group","volume":"44","author":"Allain","year":"2000","journal-title":"Eur Neurol"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib2","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/sj.ijir.3900934","article-title":"Selegiline enhances erectile activity induced by dopamine injection in the paraventricular nucleus of the hypothalamus in anesthetized rats","volume":"14","author":"Allard","year":"2002","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4088\/JCP.v64n0216","article-title":"A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder","volume":"64","author":"Amsterdam","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib4","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/01.jcp.0000239794.37073.70","article-title":"Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial","volume":"26","author":"Amsterdam","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib5","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/BF00978365","article-title":"Monoamine oxidase inhibitors and the cheese effect","volume":"18","author":"Anderson","year":"1993","journal-title":"Neurochem Res"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib6","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1177\/0091270006289852","article-title":"Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6\u00a0mg\/24\u00a0h in healthy subjects","volume":"46","author":"Azzaro","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s007020170047","article-title":"Pharmacotherapy of depression: a historical analysis","volume":"108","author":"Ban","year":"2001","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib8","first-page":"112","article-title":"Systematic studies with levomepromazine","volume":"4","author":"Ban","year":"1963","journal-title":"J Neuropsychiatr"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/(SICI)1099-081X(199703)18:2<165::AID-BDD14>3.0.CO;2-S","article-title":"Toxicokinetic evaluation of a selegiline transdermal system in the dog","volume":"18","author":"Barrett","year":"1997","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib10","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0893-133X(98)00092-X","article-title":"Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria","volume":"20","author":"Bartzokis","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib11","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1046\/j.1360-0443.2003.00524.x","article-title":"A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation","volume":"98","author":"Biberman","year":"2003","journal-title":"Addiction"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1192\/bjp.113.497.349","article-title":"Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs","volume":"113","author":"Blackwell","year":"1967","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1017\/S1092852900020496","article-title":"Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6\u00a0mg\/24\u00a0hour","volume":"12","author":"Blob","year":"2007","journal-title":"CNS Spectr"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib14","series-title":"EMSAM Prescribing Information","author":"Bristol-Myers Squibb Company (BMS)","year":"2006"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib15","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1176\/appi.ajp.159.11.1869","article-title":"Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients","volume":"159","author":"Bodkin","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib16","first-page":"171","article-title":"The new generation of monoamine oxidase inhibitors","volume":"38","author":"Cesura","year":"1992","journal-title":"Prog Drug Res"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib17","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00702-003-0036-4","article-title":"A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition","volume":"110","author":"Clarke","year":"2003","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib18","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00702-003-0042-6","article-title":"A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition","volume":"110","author":"Clarke","year":"2003","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib19","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1212\/WNL.50.3.645","article-title":"A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment","volume":"50","author":"Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11934-002-0094-4","article-title":"Advances in drug delivery: improved bioavailability and drug effect","volume":"3","author":"Dmochowski","year":"2002","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib21","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0006-2952(79)90376-9","article-title":"Does the B form selective monoamine oxidase inhibitor lose selectivity by long term treatment?","volume":"28","author":"Ekstedt","year":"1979","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.drugalcdep.2006.04.010","article-title":"Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence","volume":"85","author":"Elkashef","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib23","unstructured":"Food and Drug Administration (FDA). EMSAM selegiline transdermal system new drug application 21,336\/ 21,708. 2005 [Food and Drug Administration web site: available at http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/05\/briefing\/2005-4186B2_01_01_Somerset-EMSAM.pdf]."},{"key":"10.1016\/j.pnpbp.2007.04.020_bib24","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.4088\/JCP.v67n0905","article-title":"Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial","volume":"67","author":"Feiger","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib25","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/0006-2952(79)90293-4","article-title":"Cumulative effects of irreversible MAO inhibitors in vivo","volume":"28","author":"Felner","year":"1979","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00131746-200407000-00005","article-title":"The role of monoamine oxidase inhibitors in current psychiatric practice","volume":"10","author":"Fiedorowicz","year":"2004","journal-title":"J Psychiatr Pract"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib27","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1176\/ajp.145.10.1289","article-title":"A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder","volume":"145","author":"Frank","year":"1988","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0006-3223(02)01454-3","article-title":"A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation","volume":"53","author":"George","year":"2003","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0091-3057(99)00016-7","article-title":"Oral versus transdermal selegiline: antidepressant-like activity in rats","volume":"63","author":"Gordon","year":"1999","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib30","unstructured":"Henzl M. The Promise of Transdermal Drug Delivery-Not Only for Reproductive Steroids. Business Briefing North American Pharmacotherpy. Available at http:\/\/www.touchbriefings.com\/pdf\/790\/14-henzl.pdf."},{"key":"10.1016\/j.pnpbp.2007.04.020_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00213-003-1616-6","article-title":"Transdermal selegiline and intravenous cocaine: safety and interactions","volume":"172","author":"Houtsmuller","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1001\/archpsyc.56.5.431","article-title":"Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial","volume":"56","author":"Jarrett","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib33","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.65.2_suppl_1.S3","article-title":"A novel dopamine agonist for the transdermal treatment of Parkinson's disease","volume":"65","author":"Jenner","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib34","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.pnpbp.2006.03.031","article-title":"Advances in psychotropic formulations","volume":"30","author":"Keith","year":"2006","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0047-6374(85)90001-6","article-title":"The facilitation of dopaminergic activity in the aged brain by (\u2212)deprenyl. A proposal for a strategy to improve the quality of life in senescence","volume":"30","author":"Knoll","year":"1985","journal-title":"Mech Ageing Dev"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-0773.1998.tb01399.x","article-title":"(\u2212)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain","volume":"82","author":"Knoll","year":"1998","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib37","first-page":"179","article-title":"(\u2212)Deprenyl (Selegiline): past, present and future","volume":"8","author":"Knoll","year":"2000","journal-title":"Neurobiol. (Bp)"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib38","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1046\/j.1468-1331.1999.650539.x","article-title":"Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian\u2013Danish Study Group","volume":"6","author":"Larsen","year":"1999","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/archpsyc.1988.01800260037004","article-title":"Antidepressant specificity in atypical depression","volume":"45","author":"Liebowitz","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0022-510X(95)00240-1","article-title":"Delayed development of symptomatic improvement by (\u2212)-deprenyl in Parkinson's disease","volume":"134","author":"Mally","year":"1995","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/archpsyc.1989.01810010047007","article-title":"A controlled study of the antidepressant efficacy and side effects of (\u2212)-deprenyl. A selective monoamine oxidase inhibitor","volume":"46","author":"Mann","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.2042-7158.2003.tb02430.x","article-title":"Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues","volume":"55","author":"Mawhinney","year":"2003","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib43","first-page":"63","article-title":"A placebo-controlled trial of l-deprenyl in atypical depression","volume":"25","author":"McGrath","year":"1989","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib45","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1176\/ajp.150.1.118","article-title":"A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression","volume":"150","author":"McGrath","year":"1993","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib44","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1176\/appi.ajp.157.3.344","article-title":"A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression","volume":"157","author":"McGrath","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib46","first-page":"18","article-title":"Transdermal MAO inhibitor patch effective for ADHD","volume":"31","author":"Mechcatie","year":"2003","journal-title":"NewsClin Psychiatr News"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib47","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1212\/WNL.51.2.520","article-title":"Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group","volume":"51","author":"Palhagen","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib48","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1017\/S1092852900014498","article-title":"Transdermal selegiline: the new generation of monoamine oxidase inhibitors","volume":"11","author":"Patkar","year":"2006","journal-title":"CNS Spectr"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib49","first-page":"179","article-title":"Selegiline Transdermal System (STS): assessment of dermal safety in human","volume":"23","author":"Pauporte","year":"2004","journal-title":"J Toxicol"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib50","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1468-1331.1999.tb00007.x","article-title":"SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa","volume":"6","author":"Przuntek","year":"1999","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib51","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1176\/ajp.145.3.306","article-title":"Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders","volume":"145","author":"Quitkin","year":"1988","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib52","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1192\/S0007125000292465","article-title":"Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo","author":"Quitkin","year":"1993","journal-title":"Br J Psychiatry Suppl"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib53","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1176\/ajp.155.9.1247","article-title":"Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment","volume":"155","author":"Reimherr","year":"1998","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib54","first-page":"124","article-title":"Monoamine oxidase inhibitors: a new generation","volume":"36","author":"Robinson","year":"2002","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib55","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/archpsyc.1973.04200030093015","article-title":"The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive-anxiety states. A controlled clinical trial","volume":"29","author":"Robinson","year":"1973","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib56","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/(SICI)1099-081X(199711)18:8<665::AID-BDD47>3.0.CO;2-A","article-title":"Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system","volume":"18","author":"Rohatagi","year":"1997","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1098-108X(199401)15:1<1::AID-EAT2260150102>3.0.CO;2-E","article-title":"A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives","volume":"15","author":"Rothschild","year":"1994","journal-title":"Int J Eat Disord"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib58","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1212\/WNL.54.1.233","article-title":"Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study","volume":"54","author":"Sacktor","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib59","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.2042-7158.1998.tb06876.x","article-title":"Drug-delivery products and the Zydis fast-dissolving dosage form","volume":"50","author":"Seager","year":"1998","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib60","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ana.10191","article-title":"Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial","volume":"51","author":"Shoulson","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib61","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/(SICI)1520-6394(1998)7:3<126::AID-DA5>3.0.CO;2-9","article-title":"Low dose selegiline (l-Deprenyl) in social phobia","volume":"7","author":"Simpson","year":"1998","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib62","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1001\/archpsyc.1994.03950080019003","article-title":"High-dose selegiline in treatment-resistant older depressive patients","volume":"51","author":"Sunderland","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib63","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1176\/ajp.154.2.239","article-title":"Dopamine reuptake site densities in patients with social phobia","volume":"154","author":"Tiihonen","year":"1997","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib64","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/0091270003253425","article-title":"Tyramine pharmacokinetics and reduced bioavailability with food","volume":"43","author":"Vandenberg","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib65","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0006-3223(02)01892-9","article-title":"Transdermal selegiline: targeted effects on monoamine oxidases in the brain","volume":"54","author":"Wecker","year":"2003","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib66","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/gps.545","article-title":"The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials","volume":"17","author":"Wilcock","year":"2002","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.04.020_bib67","article-title":"Transdermal Drug Delivery","volume":"28","author":"Wilkosz","year":"2003","journal-title":"PART 1: Curr status. US Pharmacist"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584607001546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584607001546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T21:26:10Z","timestamp":1556400370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584607001546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0278584607001546"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2007.04.020","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}